
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Vonoprazan–Tetracycline Dual Regimen as Rescue Therapy for Helicobacter pylori Infection: Randomized Controlled Trial</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>Vonoprazan–Tetracycline Dual Regimen as Rescue Therapy for Helicobacter pylori Infection: Randomized Controlled Trial</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Gastroenterology, Accepted 6 January 2026</li>
<li style="margin-left: 0px;">Topic: Helicobacter pylori rescue therapy (second-line treatment)</li>
<li style="margin-left: 0px;">Authors: Gao W, Li J, Yang G, et al.</li>
</ul>
<details><summary><strong>1. Background and Rationale</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">H. pylori is a Gram-negative bacterium colonizing the human stomach, affecting nearly half of the global population</li>
<li style="margin-left: 0px;">Antimicrobial treatment remains primary approach to limit bacterial transmission, promote gastric lesion healing, and reduce gastric cancer risk</li>
<li style="margin-left: 0px;">Simplified dual regimens using a single sensitive antibiotic have emerged as feasible alternative with growing challenge of antibiotic resistance</li>
<li style="margin-left: 0px;">In Asia, dual therapy with vonoprazan and amoxicillin has demonstrated high eradication rates and good tolerability</li>
<li style="margin-left: 0px;">Tetracycline serves as compelling alternative due to persistently low resistance rate (typically &lt;3%) and established role in bismuth quadruple therapy</li>
<li style="margin-left: 0px;">Prior retrospective study by authors showed VT dual regimen achieved eradication rate of 90.9% (40/44) as rescue therapy</li>
</ul>
</div></details>
<details><summary><strong>2. Study Design and Methods</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>2.1 Trial Overview</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prospective, open-label, randomized controlled non-inferiority trial</li>
<li style="margin-left: 0px;">Conducted from February 2024 to July 2025 at Peking University First Hospital, Beijing, China</li>
<li style="margin-left: 0px;">Approved by Ethics Committee of Peking University First Hospital</li>
<li style="margin-left: 0px;">Conducted in accordance with Declaration of Helsinki</li>
<li style="margin-left: 0px;">Registered at chictr.org.cn (ChiCTR2400080705)</li>
<li style="margin-left: 0px;">Followed CONSORT guidelines for randomized controlled studies</li>
</ul>
</div></details>
<details><summary><strong>2.2 Eligibility Criteria</strong></summary><div style="padding-left: 20px;">
<p><strong>Inclusion criteria:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Adults aged 18-80 years with confirmed H. pylori infection (positive 13C-urea breath test)</li>
<li style="margin-left: 0px;">At least one prior eradication failure, irrespective of number of previous treatment attempts</li>
</ul>
<p><strong>Exclusion criteria:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prior use of regimen containing PPI + bismuth + tetracycline + metronidazole in combination</li>
<li style="margin-left: 0px;">Use of antibiotics, bismuth, or PPI within 4 weeks prior to enrollment</li>
<li style="margin-left: 0px;">Pregnancy or breastfeeding</li>
<li style="margin-left: 0px;">Presence of severe comorbidities (advanced hepatic, cardiac, or renal disease; malignancy; alcohol dependence)</li>
<li style="margin-left: 0px;">Known hypersensitivity to study medications or components</li>
<li style="margin-left: 0px;">Participation in another clinical drug trial within 3 months prior</li>
<li style="margin-left: 0px;">Inability to communicate effectively due to psychiatric conditions or severe neurosis</li>
<li style="margin-left: 0px;">Any other condition deemed by investigator unsuitable for participation</li>
</ul>
</div></details>
<details><summary><strong>2.3 Randomization and Interventions</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Patients randomly assigned in 1:1 ratio to VT dual therapy or standard BQT</li>
<li style="margin-left: 0px;">Computer-generated random number sequence with block size of 4</li>
<li style="margin-left: 0px;">Assignments concealed in sequentially numbered, opaque, sealed envelopes</li>
<li style="margin-left: 0px;">Open-label study (both investigators and participants aware of treatment allocation)</li>
<li style="margin-left: 0px;">Technicians conducting 13C-urea breath tests remained blinded to group allocation</li>
</ul>
<p><strong>VT Dual Therapy (n=175):</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Vonoprazan 20 mg twice daily (Takeda Pharmaceutical Co.)</li>
<li style="margin-left: 0px;">Tetracycline 500 mg three times daily (Guilin Pharmaceutical Co., Ltd.)</li>
</ul>
<p><strong>BQT (Bismuth Quadruple Therapy, n=175):</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Lansoprazole 30 mg twice daily (Takeda Pharmaceutical Co.)</li>
<li style="margin-left: 0px;">Colloidal bismuth 150 mg three times daily (North China Pharmaceutical Co.)</li>
<li style="margin-left: 0px;">Tetracycline 500 mg three times daily (Guilin Pharmaceutical Co., Ltd.)</li>
<li style="margin-left: 0px;">Metronidazole 400 mg three times daily (Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.)</li>
<li style="margin-left: 0px;">Treatment duration: 14 consecutive days for both regimens</li>
<li style="margin-left: 0px;">PPI, vonoprazan, and bismuth taken ~30 minutes before meals</li>
<li style="margin-left: 0px;">Tetracycline and metronidazole taken immediately after meals</li>
</ul>
</div></details>
<details><summary><strong>2.4 Outcome Measures</strong></summary><div style="padding-left: 20px;">
<p><strong>Primary outcome:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Rate of successful H. pylori eradication, determined via 13C-urea breath testing at 8-week follow-up (6 weeks after treatment completion)</li>
</ul>
<p><strong>Secondary outcomes:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Adverse event frequency and severity</li>
<li style="margin-left: 0px;">Medication adherence</li>
</ul>
</div></details>
<details><summary><strong>2.5 Sample Size Calculation</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Randomized, active-control, parallel-group study designed to test non-inferiority</li>
<li style="margin-left: 0px;">One-sided significance level (α) of 0.025, with Bonferroni correction allocating α = 0.0125 to each individual comparison</li>
<li style="margin-left: 0px;">Statistical power: 80% (β = 0.20)</li>
<li style="margin-left: 0px;">Non-inferiority margin: predefined at 10%</li>
<li style="margin-left: 0px;">Expected eradication rate for BQT as rescue therapy: 88% [11]</li>
<li style="margin-left: 0px;">Required sample size: 166 patients per group</li>
<li style="margin-left: 0px;">Anticipated dropout rate: ~5%</li>
<li style="margin-left: 0px;">Planned total sample size: 350 participants (175 per arm)</li>
</ul>
</div></details>
<details><summary><strong>2.6 Statistical Analysis Populations</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Intention-to-treat (ITT):</strong> All enrolled patients with at least 2 months of follow-up; any loss to follow-up counted as treatment failure</li>
<li style="margin-left: 0px;"><strong>Modified intention-to-treat (mITT):</strong> Patients who received at least one dose of study medication and completed 13C-UBT at least 6 weeks after treatment, regardless of adherence</li>
<li style="margin-left: 0px;"><strong>Per-protocol (PP):</strong> Patients who completed follow-up and took at least 80% of prescribed medications</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Results</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Patient Enrollment and Baseline Characteristics</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Of 382 individuals screened for eligibility, 350 were ultimately randomized: 175 assigned to VT dual therapy group and 175 to BQT group</li>
<li style="margin-left: 0px;">Final follow-up assessments completed in July 2025</li>
<li style="margin-left: 0px;">All participants had previously failed H. pylori eradication therapy</li>
</ul>
<p><strong>Baseline demographic and clinical characteristics:</strong></p>
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Characteristic</th>
<th>VT Group (n=175)</th>
<th>BQT Group (n=175)</th>
<th>P value</th>
</tr></thead>
<tbody>
<tr>
<td>Age (mean, SD)</td>
<td>48 (13.4) years</td>
<td>45.7 (12.1) years</td>
<td>0.10</td>
</tr>
<tr>
<td>Age range</td>
<td>18-77 years</td>
<td>18-73 years</td>
<td>-</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>60/115</td>
<td>66/109</td>
<td>0.58</td>
</tr>
<tr>
<td>Body weight (mean, SD)</td>
<td>63.5 (12.4) kg</td>
<td>63.3 (11.2) kg</td>
<td>0.90</td>
</tr>
<tr>
<td>BMI (mean, SD)</td>
<td>23 (3.5) kg/m²</td>
<td>23 (3) kg/m²</td>
<td>0.89</td>
</tr>
<tr>
<td>Cigarette smoking</td>
<td>15 (8.6%)</td>
<td>9 (5.1%)</td>
<td>0.29</td>
</tr>
<tr>
<td>Alcohol drinking</td>
<td>30 (17.1%)</td>
<td>31 (17.7%)</td>
<td>1</td>
</tr>
<tr>
<td>Family history of gastric cancer</td>
<td>17 (9.7%)</td>
<td>20 (11.4%)</td>
<td>0.73</td>
</tr>
<tr>
<td>Penicillin allergy</td>
<td>63 (36%)</td>
<td>56 (32%)</td>
<td>0.50</td>
</tr>
</tbody>
</table>
<p><strong>Endoscopic diagnosis:</strong></p>
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Finding</th>
<th>VT Group</th>
<th>BQT Group</th>
<th>P value</th>
</tr></thead>
<tbody>
<tr>
<td>Gastritis</td>
<td>153 (87.4%)</td>
<td>148 (84.6%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Chronic superficial gastritis (CSG)</td>
<td>103 (58.9%)</td>
<td>92 (52.6%)</td>
<td>0.28</td>
</tr>
<tr>
<td>Chronic atrophic gastritis (CAG)</td>
<td>49 (28%)</td>
<td>56 (32%)</td>
<td>0.48</td>
</tr>
<tr>
<td>Peptic ulcer</td>
<td>22 (12.6%)</td>
<td>27 (15.4%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Gastric ulcer</td>
<td>4 (2.3%)</td>
<td>7 (4%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Duodenal ulcer</td>
<td>15 (8.6%)</td>
<td>18 (10.3%)</td>
<td>0.72</td>
</tr>
<tr>
<td>Complex ulcer</td>
<td>3 (1.7%)</td>
<td>2 (1.1%)</td>
<td>1</td>
</tr>
</tbody>
</table>
<p><strong>Concomitant diseases:</strong></p>
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Condition</th>
<th>VT Group</th>
<th>BQT Group</th>
<th>P value</th>
</tr></thead>
<tbody>
<tr>
<td>Any concomitant disease</td>
<td>111 (63.4%)</td>
<td>103 (58.9%)</td>
<td>0.44</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>11 (6.3%)</td>
<td>9 (5.1%)</td>
<td>0.82</td>
</tr>
<tr>
<td>Hypertension</td>
<td>21 (12%)</td>
<td>23 (13.1%)</td>
<td>0.87</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>36 (20.6%)</td>
<td>26 (14.9%)</td>
<td>0.21</td>
</tr>
<tr>
<td>Heart disease</td>
<td>7 (4%)</td>
<td>11 (6.3%)</td>
<td>0.47</td>
</tr>
<tr>
<td>Lung disease</td>
<td>7 (4%)</td>
<td>2 (1.1%)</td>
<td>0.17</td>
</tr>
<tr>
<td>Liver disease</td>
<td>19 (10.9%)</td>
<td>11 (6.3%)</td>
<td>0.18</td>
</tr>
<tr>
<td>Renal disease</td>
<td>12 (6.9%)</td>
<td>9 (5.1%)</td>
<td>0.65</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>3 (1.7%)</td>
<td>1 (0.6%)</td>
<td>0.62</td>
</tr>
<tr>
<td>Autoimmune disease</td>
<td>16 (9.1%)</td>
<td>13 (7.4%)</td>
<td>0.70</td>
</tr>
<tr>
<td>Hypersensitivity disease</td>
<td>10 (5.7%)</td>
<td>11 (6.3%)</td>
<td>1</td>
</tr>
<tr>
<td>Malignant tumor</td>
<td>7 (4%)</td>
<td>3 (1.7%)</td>
<td>0.34</td>
</tr>
<tr>
<td>Combined medicine use</td>
<td>60 (34.3%)</td>
<td>54 (30.9%)</td>
<td>0.57</td>
</tr>
</tbody>
</table>
<p><strong>Previous treatment characteristics:</strong></p>
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Variable</th>
<th>VT Group (n=175)</th>
<th>BQT Group (n=175)</th>
<th>P value</th>
</tr></thead>
<tbody>
<tr>
<td>Previous treatment times (median, IQR)</td>
<td>2 (1-3)</td>
<td>2 (1-2)</td>
<td>0.052</td>
</tr>
<tr>
<td>1 prior failure</td>
<td>65 (37.1%)</td>
<td>77 (44%)</td>
<td>0.23</td>
</tr>
<tr>
<td>2 prior failures</td>
<td>55 (31.4%)</td>
<td>59 (33.7%)</td>
<td>0.73</td>
</tr>
<tr>
<td>≥3 prior failures</td>
<td>55 (31.4%)</td>
<td>39 (22.3%)</td>
<td>0.07</td>
</tr>
</tbody>
</table>
<p><strong>Previous eradication regimen types:</strong></p>
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Regimen Type</th>
<th>VT Group</th>
<th>BQT Group</th>
<th>P value</th>
</tr></thead>
<tbody>
<tr>
<td>Tetracycline-based</td>
<td>8 (4.6%)</td>
<td>6 (3.4%)</td>
<td>0.79</td>
</tr>
<tr>
<td>Clarithromycin-based</td>
<td>156 (89.1%)</td>
<td>161 (92.0%)</td>
<td>0.47</td>
</tr>
<tr>
<td>Levofloxacin-based</td>
<td>68 (38.9%)</td>
<td>78 (44.6%)</td>
<td>0.33</td>
</tr>
<tr>
<td>Metronidazole-based</td>
<td>95 (54.3%)</td>
<td>79 (45.1%)</td>
<td>0.11</td>
</tr>
<tr>
<td>Furazolidone-based</td>
<td>25 (14.3%)</td>
<td>16 (9.1%)</td>
<td>0.18</td>
</tr>
<tr>
<td>Cephalosporin-based</td>
<td>6 (3.4%)</td>
<td>7 (4.0%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Amoxicillin-based (times, median, IQR)</td>
<td>1 (0-2)</td>
<td>1 (0-2)</td>
<td>0.48</td>
</tr>
<tr>
<td>No prior amoxicillin use</td>
<td>57 (32.6%)</td>
<td>50 (28.6%)</td>
<td>0.49</td>
</tr>
<tr>
<td>1 prior amoxicillin course</td>
<td>46 (26.3%)</td>
<td>63 (36.0%)</td>
<td>0.07</td>
</tr>
<tr>
<td>≥2 prior amoxicillin courses</td>
<td>72 (41.1%)</td>
<td>62 (35.4%)</td>
<td>0.32</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>3.2 Patient Flow and Disposition</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">During follow-up, 5 patients in VT group and 6 in BQT group were lost to follow-up (did not undergo 13C-UBT)</li>
<li style="margin-left: 0px;">These 11 patients classified as treatment failures in ITT analysis and excluded from mITT population</li>
<li style="margin-left: 0px;">Two patients in VT group and 16 in BQT group discontinued treatment (consuming &lt;80% of prescribed</li>
</ul>
</div></details>
<details><summary><strong>3.3 Eradication of H. pylori Infection</strong></summary><div style="padding-left: 20px;">
<p><strong>Intention-to-treat (ITT) analysis:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT dual therapy: 88.0% (154/175; 95% CI: 82.0%–92.2%)</li>
<li style="margin-left: 0px;">BQT: 86.3% (151/175; 95% CI: 80.1%–90.8%)</li>
<li style="margin-left: 0px;">Difference: 1.7% (95% CI: –5.9% to 9.3%)</li>
<li style="margin-left: 0px;">P value for difference: 0.75</li>
<li style="margin-left: 0px;">Non-inferiority P: 0.0005</li>
</ul>
<p><strong>Modified intention-to-treat (mITT) analysis:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT dual therapy: 90.6% (154/170; 95% CI: 84.9%–94.4%)</li>
<li style="margin-left: 0px;">BQT: 89.3% (151/169; 95% CI: 83.5%–93.4%)</li>
<li style="margin-left: 0px;">Difference: 1.2% (95% CI: –5.7% to 8.2%)</li>
<li style="margin-left: 0px;">P value for difference: 0.84</li>
<li style="margin-left: 0px;">Non-inferiority P: 0.0003</li>
</ul>
<p><strong>Per-protocol (PP) analysis:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT dual therapy: 91.1% (153/168; 95% CI: 85.4%–94.7%)</li>
<li style="margin-left: 0px;">BQT: 92.2% (141/153; 95% CI: 86.4%–95.7%)</li>
<li style="margin-left: 0px;">Difference: –1.1% (95% CI: –7.8% to 5.6%)</li>
<li style="margin-left: 0px;">P value for difference: 0.88</li>
<li style="margin-left: 0px;">Non-inferiority P: 0.002</li>
</ul>
<p>No statistically significant difference in eradication efficacy was observed between the two treatment groups across ITT, mITT, and PP analyses. VT dual therapy achieved predefined non-inferiority endpoint compared with BQT as rescue treatment.</p>
<p><strong>Eradication rates by penicillin allergy status (mITT analysis):</strong></p>
<p><em>VT group:</em></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Patients without penicillin allergy: 91.8% (101/110; 95% CI: 86.4%–95.2%)</li>
<li style="margin-left: 0px;">Patients with penicillin allergy: 88.3% (53/60; 95% CI: 79.8%–93.5%)</li>
<li style="margin-left: 0px;">Absolute difference: +3.5% (95% CI: –6.1% to 13.1%)</li>
<li style="margin-left: 0px;">P value: 0.48</li>
</ul>
<p><em>BQT group:</em></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Patients without penicillin allergy: 89.4% (101/113; 95% CI: 83.6%–93.2%)</li>
<li style="margin-left: 0px;">Patients with penicillin allergy: 89.3% (50/56; 95% CI: 80.6%–94.3%)</li>
<li style="margin-left: 0px;">Absolute difference: +0.1% (95% CI: –9.8% to 10.0%)</li>
<li style="margin-left: 0px;">P value: 0.98</li>
</ul>
<p>No significant difference in eradication rates between patients with or without penicillin allergy in either group.</p>
</div></details>
<details><summary><strong>3.4 Adverse Events and Adherence</strong></summary><div style="padding-left: 20px;">
<p><strong>Treatment-emergent adverse events (TEAEs):</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT group: 10.9% (19/175)</li>
<li style="margin-left: 0px;">BQT group: 45.7% (80/175)</li>
<li style="margin-left: 0px;">P value: &lt;0.001</li>
</ul>
<p><strong>TEAE severity grading:</strong></p>
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Severity</th>
<th>VT Group</th>
<th>BQT Group</th>
<th>P value</th>
</tr></thead>
<tbody>
<tr>
<td>Mild</td>
<td>13</td>
<td>54</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Moderate</td>
<td>4</td>
<td>10</td>
<td>0.17</td>
</tr>
<tr>
<td>Severe</td>
<td>2</td>
<td>16</td>
<td>0.001</td>
</tr>
<tr>
<td>Moderate to severe combined</td>
<td>6</td>
<td>26</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
<p><strong>Specific adverse events:</strong></p>
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Adverse Event</th>
<th>VT Group</th>
<th>BQT Group</th>
</tr></thead>
<tbody>
<tr>
<td>Nausea</td>
<td>3</td>
<td>37</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>1</td>
<td>12</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>Bitter taste</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Constipation</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Fever</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Headache</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Loss of appetite</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Abdominal distension</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Abdominal discomfort</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Itchy skin</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Rash</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Palpitation</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Transient mild liver dysfunction</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Chest tightness</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Hypogeusia</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Chest pain</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Transient hand tremors</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Muscle pain</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Dreaminess</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Glossitis</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>
<p><strong>Discontinuation due to AEs:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT group: 0/175 (0.0%)</li>
<li style="margin-left: 0px;">BQT group: 15/175 (8.6%)</li>
<li style="margin-left: 0px;">P value: &lt;0.001</li>
</ul>
<p><strong>Adherence rates:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT group: 168/175 (96.0%)</li>
<li style="margin-left: 0px;">BQT group: 153/175 (87.4%)</li>
<li style="margin-left: 0px;">P value: 0.006</li>
</ul>
<p><strong>Adherence according to AE severity:</strong></p>
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>AE Severity</th>
<th>VT Group</th>
<th>BQT Group</th>
</tr></thead>
<tbody>
<tr>
<td>Mild</td>
<td>13/13 (100.0%)</td>
<td>54/54 (100.0%)</td>
</tr>
<tr>
<td>Moderate</td>
<td>4/4 (100.0%)</td>
<td>10/10 (100.0%)</td>
</tr>
<tr>
<td>Severe</td>
<td>2/2 (100.0%)</td>
<td>4/16 (25.0%)</td>
</tr>
</tbody>
</table>
<p>No hospitalizations or deaths occurred in either group. All events resolved without intervention after treatment cessation.</p>
</div></details>
</div></details>
<details><summary><strong>4. Discussion</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.1 Main Findings</strong></summary><div style="padding-left: 20px;">
<p>This randomized clinical trial demonstrated that vonoprazan-tetracycline (VT) dual therapy is non-inferior to bismuth quadruple therapy (BQT) as rescue treatment for H. pylori infection in patients with prior eradication failure. Among 350 enrolled participants, VT regimen achieved high eradication rates across ITT, mITT, and PP analyses, comparable to standard BQT. This is the first prospective evaluation of vonoprazan combined with tetracycline as a simplified, penicillin-free rescue regimen.</p>
</div></details>
<details><summary><strong>4.2 Mechanistic Rationale</strong></summary><div style="padding-left: 20px;">
<p>Success of H. pylori eradication depends heavily on intensity, consistency, and duration of acid suppression. Although amoxicillin-based dual therapies were proposed decades ago, eradication rates became consistently favorable only when combined with double-dose PPIs or standard-dose P-CABs. Potent acid suppression broadens applicability of dual therapy, allowing a single sensitive antibiotic to achieve reliable eradication when gastric pH is maintained ≥6 with P-CABs. This pharmacologic rationale explains favorable outcomes observed with VT dual therapy compared with omeprazole-tetracycline dual therapy in earlier studies.</p>
</div></details>
<details><summary><strong>4.3 Antibiotic Resistance Considerations</strong></summary><div style="padding-left: 20px;">
<p>Antibiotic resistance is a major obstacle to successful eradication of H. pylori, particularly in rescue treatment. Surveillance data from Asia-Pacific region (1990–2022) showed persistently high resistance rates to metronidazole (52%), levofloxacin (26%), and clarithromycin (22%), while resistance to tetracycline and amoxicillin remained low at approximately 4%. These findings emphasize value of empiric regimens built on low-resistance antibiotics. Tetracycline stands out not only due to low primary resistance but also because its resistance profile remains stable even after prior treatment failures.</p>
</div></details>
<details><summary><strong>4.4 Comparison with Previous Studies</strong></summary><div style="padding-left: 20px;">
<p>In previous randomized trial, vonoprazan combined with tetracycline yielded eradication rate of 94.5% (mITT) in treatment-naïve patients. In real-world cohort of patients</p>
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
